Webinars and Commercial Conversations — Register Now

Tuesday, December 1, 2026, 1 PM-2 PM ET

Join UCSF clinical microbiologists as they share their journey from using multiple respiratory testing platforms to implementing a flexible, stewardship-driven testing strategy. Learn how customizable respiratory panels helped streamline workflows, improve efficiency, and better align testing with patient needs.

Webinar presenters Danielle Ingebrigtsen, MHS, Clinical Laboratory Scientist Supervisor, UCSF Health, and Rama Yakubu, MD, PhD, Assistant Professor of Laboratory Medicine, Co-Director of Microbiology, UCSF Health.

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diasorin.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, January 12, 2027, 2 PM-3 PM ET
Hear Dr. Roden discuss how computational pathology will impact the practice & future of precision oncology, using global real world analytical evidence for the novel TROP2 NMR biomarker as an example.

Webinar presenter Anja C. Roden, MD, Consultant, Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science, Rochester, Minnesota

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Roche Diagnostics. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

November 2026

New ferritin thresholds for iron deficiency

November 2026—Fixing a problem may start with identifying it, but naming is often only the starting pistol in a much longer race. The distance between recognizing the issues of iron deficiency and related anemia, and providing a diagnosis and treatment, can often stretch months to years. Improvements in the field have been more tortoise than hare. But the pace may be picking up. This fall, the American Society …

Broad guidance for labs on gender diversity

November 2026—The first broad set of recommendations for gender-diverse patient care, endorsed by the ADLM and published in July, spell out how to interpret routine testing in this population—and go far beyond. They cover not only laboratory medicine but also anatomic pathology and informatics. Gender-affirming hormone therapy affects a relatively small group of laboratory tests, and decades of research have shown the test results can be interpreted in accordance with the patient’s affirmed gender, with a few exceptions. Tiffany Thomas, PhD, coauthor of the guidance and assistant professor in the Department of Pathology and Cell Biology at Columbia University, uses a flowchart-like way to describe the logic: “Is somebody on gender-affirming hormone therapy [GAHT]? If yes, know what few lab tests are affected by that. If it’s based on the affirmed gender, then you generally go with that.”

Assay capacity vital to control of C. auris outbreak

November 2026—A 2024 outbreak of Candidozyma auris at Harborview Medical Center in Seattle made clear the efficacy of high-throughput PCR screening in containing a C. auris outbreak. At Harborview, it did so before the onset of a single clinical infection. It was one of Washington State’s first hospital outbreaks due to C. auris, occurring one year after its first detection in Washington in 2023. “I think we were the 29th state in the country to have C. auris,” says Alex Greninger, MD, PhD, MS, MPhil, head of the Division of Infectious Disease Diagnostics, Department of Laboratory Medicine and Pathology, and the Larry Corey endowed professor of laboratory medicine and pathology, University of Washington School of Medicine.

In hematology, turning the promise of AI into practice

November 2026—Artificial intelligence has enormous potential to change hematology practice, but achieving that potential will require more than better algorithms. What’s needed and how to move the field forward is what Amrom Obstfeld, MD, PhD, chair of the International Council for Standardisation in Haematology, spoke to at the ADLM meeting this summer. Work on interesting applications in hematology is underway, he said, noting a couple of examples, and the AI possibilities look promising. In Dr. Obstfeld’s view, it appears a bottleneck is behind more machine learning not yet having made its way into hematology laboratories.

Parasitology benchtop guide ed. 2: a new visual reference

November 2026—CAP Publications released this fall the latest edition of its Parasitology Benchtop Reference Guide—An Illustrated Guide to Commonly Encountered Parasites. In the new edition are updated images of Cyclospora species, Cystoisospora belli, and microsporidia, in addition to nomenclature updates and others.

AMP case report: Discordance of FLT3-ITD mutation testing in AML between specimens: prognostic implications and reporting options

November 2026—Acute myeloid leukemia (AML) is a rapidly progressing and life-threatening hematologic malignancy characterized by the clonal expansion of immature myeloid cells (“blasts”) in the bone marrow, peripheral blood, and occasionally extramedullary tissues. The disruption of hematopoietic processes, such as erythropoiesis and megakaryopoiesis, can result in clinically significant cytopenias and subsequent bone marrow failure. The overall prognosis is poor, with a five-year survival rate estimated to be around 39 percent.

For greater simplicity, an LIS orchestration platform

November 2026—The laboratory can be seen as the diagnostic ecosystem for the entire enterprise. As such, the laboratory information system, or LIS, is the CNS, or central nervous system, said Liron Pantanowitz, MD, PhD, MHA, of UPMC/University of Pittsburgh. “It’s the digital backbone to everything.”

Beyond histology: TissueCypher for Barrett’s esophagus

November 2026—This conversation is part of a series of one-on-one virtual roundtables in which CAP TODAY publisher Bob McGonnagle speaks with one vendor and one laboratory expert to spotlight a company and a customer for their laboratory solutions and work. He spoke on Aug. 6 with Emmanuel Gorospe, MD, MPH, GI medical director for Castle Biosciences, and Daniel Jondle, MD, gastrointestinal pathologist and director of the Arizona Digestive Health pathology laboratory. Dr. Jondle is a paid speaker of Castle and was compensated for his participation in this roundtable session.

From the President’s Desk

November 2026—I had the pleasure last month of hosting the first-ever Global Community Reception at our CAP26 annual meeting in Las Vegas. It was a gathering of pathology leaders from outside the United States as well as senior leadership members from the CAP.

Clinical pathology selected abstracts

November 2026—Alpha-gal syndrome (AGS) is a newly described emerging noninfectious tickborne disease characterized by an allergic reaction to galactose-a-1,3-galactose (alpha-gal), an oligosaccharide found in red (mammalian) meat and other animal products, such as gelatin and dairy. As of 2022, an estimated 450,000 people in the United States had developed AGS.